Blair, Lily M. http://orcid.org/0000-0003-4739-5161
Juan, Joseph M.
Sebastian, Lafia
Tran, Vy B.
Nie, Wensheng
Wall, Gregory D.
Gerceker, Mehmet
Lai, Ian K.
Apilado, Edwin A.
Grenot, Gabriel
Amar, David
Foggetti, Giorgia
Do Carmo, Mariana
Ugur, Zeynep
Deng, Debbie
Chenchik, Alex
Paz Zafra, Maria
Dow, Lukas E. http://orcid.org/0000-0001-7048-1418
Politi, Katerina
MacQuitty, Jonathan J.
Petrov, Dmitri A.
Winslow, Monte M.
Rosen, Michael J. http://orcid.org/0000-0002-8842-6692
Winters, Ian P. http://orcid.org/0000-0002-3497-3228
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R44CA250672-01)
Article History
Received: 30 January 2023
Accepted: 2 October 2023
First Online: 12 October 2023
Competing interests
: L.M.B., J.M.J., L.S., V.B.T., G.D.W., M.G., I.K.L., E.A.A., G.G., D.A., J.J.M., and M.J.R. are current or former employees and shareholders of D2G Oncology. I.P.W. is a co-founder, employee, and shareholder of D2G Oncology. D.A.P. and M.M.W. are co-founders, shareholders, members of the board of directors, and compensated scientific advisors of D2G Oncology. I.P.W., D.A.P., and M.M.W. are co-inventors of patents relating to technologies for autochthonous mouse models of human cancer, which D2G Oncology has exclusively licensed from Stanford University. D.D. and A.C. are employees and shareholders of Cellecta. L.E.D. is a scientific advisor and holds equity in Mirimus. L.E.D., M.P.Z., and Cornell University have licensed the technology described in this manuscript. K.P. is co-inventor on a patent related to EGFR T790M mutation testing issued, licensed, and with royalties paid from MSKCC/MolecularMD. K.P. reports grants to her institution from Boehringer Ingelheim, AstraZeneca, Roche/Genentech, and D2G Oncology, and consulting fees from AstraZeneca and Janssen. The remaining authors declare no competing financial interests.